J&J Independence iBOT Stair-Climbing Data Need Scrutiny, FDA Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Independence Technology should prospectively evaluate user training for the Independence iBOT 3000 Advanced Mobility System specific to stair-climbing at home and test sites, FDA's Orthopaedic & Rehabilitation Devices Panel recommended Nov. 20 in Gaithersburg, Maryland
You may also be interested in...
J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.